RegulatoryCompany release

FDA accepts Biohaven's Vyglxia resubmission in spinocerebellar ataxia, sets first-quarter 2027 goal date

🇺🇸 Biohaven Ltd. (BHVN) · Thu 29 Oct 2026

Biohaven says the US regulator has treated its troriluzole resubmission as a complete response to the November 2025 action letter, with an advisory committee planned.

Biohaven has announced that the US Food and Drug Administration has accepted its resubmitted new drug application for Vyglxia (troriluzole) in spinocerebellar ataxia. The agency classed the filing as a complete response to the action letter issued in November 2025.

The FDA has set a user fee goal date in the first quarter of 2027. Biohaven also says an advisory committee is planned, although the summary available does not give a meeting date or the questions the panel will address.

The update, published with the company's third-quarter 2026 results on 29 October, also reports two licensing deals. One is with SK Biopharmaceuticals and covers Biohaven's Kv7 platform, including opakalim, in a transaction valued at $400m. The other is with Ono Pharmaceutical for MoDE IgG degraders, worth up to $100m in the near term.

Biohaven further discloses that the FDA has asked it to pause new enrolment in opakalim studies while nonclinical metabolite studies are completed. The material on file does not say how long the pause is expected to last or what the studies are intended to show.

For context, a complete response letter tells a sponsor that an application cannot be approved in its current form. A resubmission that addresses the deficiencies starts a new review clock.

What it means for your team

  • Regulatory teams should note that the Vyglxia review now runs to the first quarter of 2027, with an advisory committee expected to be part of it.
  • The FDA-requested pause on new opakalim enrolment, pending nonclinical metabolite studies, shows the agency asking for additional nonclinical data during clinical development.
  • Market-access and business-development teams may want to track the SK Biopharmaceuticals and Ono deals, which cover the Kv7 platform and MoDE IgG degraders respectively.

Company's press release (SEC filing): Biohaven Ltd. ↗

Article written by VigiEye from the official source (Biohaven Ltd.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →